Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 414

1.

Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474.

Giddens AC, Gamage SA, Kendall JD, Lee WJ, Baguley BC, Buchanan CM, Jamieson SMF, Dickson JMJ, Shepherd PR, Denny WA, Rewcastle GW.

Bioorg Med Chem. 2019 Apr 15;27(8):1529-1545. doi: 10.1016/j.bmc.2019.02.050. Epub 2019 Feb 25.

PMID:
30850264
2.

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations.

Leung EY, Askarian-Amiri ME, Singleton DC, Ferraro-Peyret C, Joseph WR, Finlay GJ, Broom RJ, Kakadia PM, Bohlander SK, Marshall E, Baguley BC.

Front Oncol. 2018 Oct 12;8:425. doi: 10.3389/fonc.2018.00425. eCollection 2018.

3.

Correction: Sarkar, D., et al. Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing. Int. J. Mol. Sci. 2017, 18, 1378.

Sarkar D, Oghabian A, Bodiyabadu PK, Joseph WR, Leung EY, Finlay GJ, Baguley BC, Askarian-Amiri ME.

Int J Mol Sci. 2018 May 2;19(5). pii: E1343. doi: 10.3390/ijms19051343. No abstract available.

4.

Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.

Zhang W, Li C, Jin Y, Liu X, Wang Z, Shaw JP, Baguley BC, Wu Z, Liu J.

Drug Deliv. 2018 Nov;25(1):611-622. doi: 10.1080/10717544.2018.1440669.

5.

Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.

Jin Y, Wu Z, Li C, Zhou W, Shaw JP, Baguley BC, Liu J, Zhang W.

Pharm Res. 2018 Jan 4;35(1):13. doi: 10.1007/s11095-017-2340-y.

PMID:
29302821
6.

The Genes of Life and Death: A Potential Role for Placental-Specific Genes in Cancer: Active retrotransposons in the placenta encode unique functional genes that may also be used by cancer cells to promote malignancy.

Macaulay EC, Chatterjee A, Cheng X, Baguley BC, Eccles MR, Morison IM.

Bioessays. 2017 Nov;39(11). doi: 10.1002/bies.201700091. Epub 2017 Oct 4. Review.

PMID:
28976008
7.

Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474.

Gamage SA, Giddens AC, Tsang KY, Flanagan JU, Kendall JD, Lee WJ, Baguley BC, Buchanan CM, Jamieson SMF, Shepherd PR, Denny WA, Rewcastle GW.

Bioorg Med Chem. 2017 Oct 15;25(20):5859-5874. doi: 10.1016/j.bmc.2017.09.025. Epub 2017 Sep 20.

PMID:
28958845
8.

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers.

Leung EY, Askarian-Amiri ME, Sarkar D, Ferraro-Peyret C, Joseph WR, Finlay GJ, Baguley BC.

Front Oncol. 2017 Sep 4;7:184. doi: 10.3389/fonc.2017.00184. eCollection 2017.

9.

Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing.

Sarkar D, Oghabian A, Bodiyabadu PK, Joseph WR, Leung EY, Finlay GJ, Baguley BC, Askarian-Amiri ME.

Int J Mol Sci. 2017 Jun 27;18(7). pii: E1378. doi: 10.3390/ijms18071378. Erratum in: Int J Mol Sci. 2018 May 02;19(5):.

10.

PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.

Silva JM, Deuker MM, Baguley BC, McMahon M.

Pigment Cell Melanoma Res. 2017 May;30(3):353-367. doi: 10.1111/pcmr.12586. Epub 2017 Apr 20.

11.

Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors.

Kendall JD, Giddens AC, Tsang KY, Marshall ES, Lill CL, Lee WJ, Kolekar S, Chao M, Malik A, Yu S, Chaussade C, Buchanan C, Jamieson SMF, Rewcastle GW, Baguley BC, Denny WA, Shepherd PR.

Bioorg Med Chem Lett. 2017 Jan 15;27(2):187-190. doi: 10.1016/j.bmcl.2016.11.078. Epub 2016 Nov 25.

PMID:
27923617
12.

ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells.

Hansji H, Leung EY, Baguley BC, Finlay GJ, Cameron-Smith D, Figueiredo VC, Askarian-Amiri ME.

Biol Direct. 2016 Nov 21;11(1):62.

13.

Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: How to reliably produce a biomimetic 3D model.

Zhang W, Li C, Baguley BC, Zhou F, Zhou W, Shaw JP, Wang Z, Wu Z, Liu J.

Anal Biochem. 2016 Dec 15;515:47-54. doi: 10.1016/j.ab.2016.10.004. Epub 2016 Oct 5.

PMID:
27717854
14.

Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate.

D'mello SA, Joseph WR, Green TN, Leung EY, During MJ, Finlay GJ, Baguley BC, Kalev-Zylinska ML.

Cell Calcium. 2016 Dec;60(6):384-395. doi: 10.1016/j.ceca.2016.09.003. Epub 2016 Sep 14.

PMID:
27659111
15.

Signaling Pathways in Melanogenesis.

D'Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME.

Int J Mol Sci. 2016 Jul 15;17(7). pii: E1144. doi: 10.3390/ijms17071144. Review.

16.

Improving drug retention in liposomes by aging with the aid of glucose.

Zhang W, Falconer JR, Baguley BC, Shaw JP, Kanamala M, Xu H, Wang G, Liu J, Wu Z.

Int J Pharm. 2016 May 30;505(1-2):194-203. doi: 10.1016/j.ijpharm.2016.03.044. Epub 2016 Mar 25.

PMID:
27021465
17.

Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative.

Reynisson J, Jaiswal JK, Barker D, D'mello SA, Denny WA, Baguley BC, Leung EY.

Cancer Cell Int. 2016 Mar 10;16:18. doi: 10.1186/s12935-016-0293-6. eCollection 2016.

18.

Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA).

Portier CJ, Armstrong BK, Baguley BC, Baur X, Belyaev I, Bellé R, Belpoggi F, Biggeri A, Bosland MC, Bruzzi P, Budnik LT, Bugge MD, Burns K, Calaf GM, Carpenter DO, Carpenter HM, López-Carrillo L, Clapp R, Cocco P, Consonni D, Comba P, Craft E, Dalvie MA, Davis D, Demers PA, De Roos AJ, DeWitt J, Forastiere F, Freedman JH, Fritschi L, Gaus C, Gohlke JM, Goldberg M, Greiser E, Hansen J, Hardell L, Hauptmann M, Huang W, Huff J, James MO, Jameson CW, Kortenkamp A, Kopp-Schneider A, Kromhout H, Larramendy ML, Landrigan PJ, Lash LH, Leszczynski D, Lynch CF, Magnani C, Mandrioli D, Martin FL, Merler E, Michelozzi P, Miligi L, Miller AB, Mirabelli D, Mirer FE, Naidoo S, Perry MJ, Petronio MG, Pirastu R, Portier RJ, Ramos KS, Robertson LW, Rodriguez T, Röösli M, Ross MK, Roy D, Rusyn I, Saldiva P, Sass J, Savolainen K, Scheepers PT, Sergi C, Silbergeld EK, Smith MT, Stewart BW, Sutton P, Tateo F, Terracini B, Thielmann HW, Thomas DB, Vainio H, Vena JE, Vineis P, Weiderpass E, Weisenburger DD, Woodruff TJ, Yorifuji T, Yu IJ, Zambon P, Zeeb H, Zhou SF.

J Epidemiol Community Health. 2016 Aug;70(8):741-5. doi: 10.1136/jech-2015-207005. Epub 2016 Mar 3. No abstract available.

19.

The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance.

Askarian-Amiri ME, Leung E, Finlay G, Baguley BC.

Methods Mol Biol. 2016;1395:207-27. doi: 10.1007/978-1-4939-3347-1_12. Review.

PMID:
26910076
20.

Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance.

Baguley BC.

Methods Mol Biol. 2016;1395:19-37. doi: 10.1007/978-1-4939-3347-1_2. Review.

PMID:
26910066
21.

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.

Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC.

PLoS One. 2015 Jul 6;10(7):e0131400. doi: 10.1371/journal.pone.0131400. eCollection 2015.

22.

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.

Sweetlove M, Wrightson E, Kolekar S, Rewcastle GW, Baguley BC, Shepherd PR, Jamieson SM.

Front Oncol. 2015 Jun 16;5:135. doi: 10.3389/fonc.2015.00135. eCollection 2015.

23.

Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling.

Marshall AJ, Lill CL, Chao M, Kolekar SV, Lee WJ, Marshall ES, Baguley BC, Shepherd PR, Denny WA, Flanagan JU, Rewcastle GW.

Bioorg Med Chem. 2015 Jul 1;23(13):3796-808. doi: 10.1016/j.bmc.2015.03.073. Epub 2015 Apr 4.

PMID:
25890698
24.

Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation.

Zhang W, Wang G, See E, Shaw JP, Baguley BC, Liu J, Amirapu S, Wu Z.

J Control Release. 2015 Apr 10;203:161-9. doi: 10.1016/j.jconrel.2015.02.026. Epub 2015 Feb 19.

PMID:
25701612
25.

Epigenetic regulation in human melanoma: past and future.

Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME.

Epigenetics. 2015;10(2):103-21. doi: 10.1080/15592294.2014.1003746. Review.

26.

Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice.

Baguley BC, Ding Q, Richardson E.

Front Oncol. 2014 Nov 5;4:310. doi: 10.3389/fonc.2014.00310. eCollection 2014.

27.

Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer.

Hansji H, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME.

Front Genet. 2014 Oct 31;5:379. doi: 10.3389/fgene.2014.00379. eCollection 2014. Review.

28.

Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.

Zhang W, Wang G, Falconer JR, Baguley BC, Shaw JP, Liu J, Xu H, See E, Sun J, Aa J, Wu Z.

Pharm Res. 2015 Apr;32(4):1451-61. doi: 10.1007/s11095-014-1551-8. Epub 2014 Oct 30.

PMID:
25355460
29.

Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin BL, Jeck WR, Souroullas GP, Darr DB, Zedek DC, Miley MJ, Baguley BC, Campbell SL, Sharpless NE.

Cancer Discov. 2014 Dec;4(12):1418-29. doi: 10.1158/2159-8290.CD-14-0729. Epub 2014 Sep 24.

30.

Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs.

Leung EY, Kim JE, Askarian-Amiri M, Joseph WR, McKeage MJ, Baguley BC.

Front Oncol. 2014 Sep 3;4:221. doi: 10.3389/fonc.2014.00221. eCollection 2014.

31.

Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.

Leung EY, Kim JE, Askarian-Amiri M, Rewcastle GW, Finlay GJ, Baguley BC.

PLoS One. 2014 Aug 29;9(8):e105792. doi: 10.1371/journal.pone.0105792. eCollection 2014.

32.

Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: stability, solubility, lipophilicity and ionization.

See E, Zhang W, Liu J, Svirskis D, Baguley BC, Shaw JP, Wang G, Wu Z.

Int J Pharm. 2014 Oct 1;473(1-2):528-35. doi: 10.1016/j.ijpharm.2014.07.033. Epub 2014 Jul 28.

PMID:
25079434
33.

Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer.

Askarian-Amiri ME, Seyfoddin V, Smart CE, Wang J, Kim JE, Hansji H, Baguley BC, Finlay GJ, Leung EY.

PLoS One. 2014 Jul 9;9(7):e102140. doi: 10.1371/journal.pone.0102140. eCollection 2014.

34.

Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.

Chen YY, Lukka PB, Joseph WR, Finlay GJ, Paxton JW, McKeage MJ, Baguley BC.

Cancer Chemother Pharmacol. 2014 Jul;74(1):25-35. doi: 10.1007/s00280-014-2469-x. Epub 2014 May 7.

PMID:
24801172
35.

Retrotransposon hypomethylation in melanoma and expression of a placenta-specific gene.

Macaulay EC, Roberts HE, Cheng X, Jeffs AR, Baguley BC, Morison IM.

PLoS One. 2014 Apr 23;9(4):e95840. doi: 10.1371/journal.pone.0095840. eCollection 2014.

36.

Evidence for the existence of triple-negative variants in the MCF-7 breast cancer cell population.

Leung E, Kim JE, Askarian-Amiri M, Finlay GJ, Baguley BC.

Biomed Res Int. 2014;2014:836769. doi: 10.1155/2014/836769. Epub 2014 Mar 4.

37.

Increased paired box transcription factor 8 has a survival function in glioma.

Hung N, Chen YJ, Taha A, Olivecrona M, Boet R, Wiles A, Warr T, Shaw A, Eiholzer R, Baguley BC, Eccles MR, Braithwaite AW, Macfarlane M, Royds JA, Slatter T.

BMC Cancer. 2014 Mar 6;14:159. doi: 10.1186/1471-2407-14-159.

38.

Review of high-dose intravenous vitamin C as an anticancer agent.

Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP.

Asia Pac J Clin Oncol. 2014 Mar;10(1):22-37. doi: 10.1111/ajco.12173. Review.

PMID:
24571058
39.

Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival.

D'mello SA, Flanagan JU, Green TN, Leung EY, Askarian-Amiri ME, Joseph WR, McCrystal MR, Isaacs RJ, Shaw JH, Furneaux CE, During MJ, Finlay GJ, Baguley BC, Kalev-Zylinska ML.

Front Oncol. 2014 Jan 13;3:333. doi: 10.3389/fonc.2013.00333. eCollection 2014 Jan 13.

40.

MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma.

Eccles MR, He S, Ahn A, Slobbe LJ, Jeffs AR, Yoon HS, Baguley BC.

Front Oncol. 2013 Sep 11;3:229. doi: 10.3389/fonc.2013.00229. Review.

41.

Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent.

Lukka PB, Chen YY, Finlay GJ, Joseph WR, Richardson E, Paxton JW, Baguley BC.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1013-22. doi: 10.1007/s00280-013-2280-0. Epub 2013 Sep 14.

PMID:
24036845
42.

Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells.

Awasthi A, Woolley AG, Lecomte FJ, Hung N, Baguley BC, Wilbanks SM, Jeffs AR, Tyndall JD.

Front Oncol. 2013 Aug 30;3:225. doi: 10.3389/fonc.2013.00225. eCollection 2013.

43.

Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines.

Kim JE, Leung E, Baguley BC, Finlay GJ.

Front Genet. 2013 May 31;4:97. doi: 10.3389/fgene.2013.00097. eCollection 2013.

44.

The role of the hippo pathway in melanocytes and melanoma.

Kim JE, Finlay GJ, Baguley BC.

Front Oncol. 2013 May 16;3:123. doi: 10.3389/fonc.2013.00123. eCollection 2013.

45.

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.

Stones CJ, Kim JE, Joseph WR, Leung E, Marshall ES, Finlay GJ, Shelling AN, Baguley BC.

Front Genet. 2013 May 8;4:66. doi: 10.3389/fgene.2013.00066. eCollection 2013.

46.

Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).

Rewcastle GW, Gamage SA, Flanagan JU, Kendall JD, Denny WA, Baguley BC, Buchanan CM, Chao M, Kestell P, Kolekar S, Lee WJ, Lill CL, Malik A, Singh R, Jamieson SM, Shepherd PR.

Eur J Med Chem. 2013 Jun;64:137-47. doi: 10.1016/j.ejmech.2013.03.038. Epub 2013 Apr 6.

PMID:
23644197
47.

Mathematical determination of cell population doubling times for multiple cell lines.

Daukste L, Basse B, Baguley BC, Wall DJ.

Bull Math Biol. 2012 Oct;74(10):2510-34. doi: 10.1007/s11538-012-9764-7. Epub 2012 Aug 23.

PMID:
22914970
48.

Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.

Lukka PB, Paxton JW, Kestell P, Baguley BC.

Cancer Chemother Pharmacol. 2012 Jul;70(1):151-60. doi: 10.1007/s00280-012-1892-0. Epub 2012 Jun 3.

PMID:
22660735
49.

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.

Kim JE, Stones C, Joseph WR, Leung E, Finlay GJ, Shelling AN, Phillips WA, Shepherd PR, Baguley BC.

BMC Cancer. 2012 Apr 4;12:141. doi: 10.1186/1471-2407-12-141.

50.

A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development.

Lukka PB, Paxton JW, Atwell GJ, Kestell P, Baguley BC.

J Pharm Biomed Anal. 2012 Apr 7;63:9-16. doi: 10.1016/j.jpba.2012.01.022. Epub 2012 Jan 28.

PMID:
22361659

Supplemental Content

Loading ...
Support Center